Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Neil A. O’Brien(University of California, Los Angeles), Dennis J. Slamon(University of California, Los Angeles)
Cited by 155
Related Papers
Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
|Clinical Cancer Research|2023|48
Role for polo-like kinase 4 in mediation of cytokinesis
|Proceedings of the National Academy of Sciences|2019|40